Pulmonary arterial hypertension (PAH) is characterized by vascular remodeling associated with obliteration of pulmonary arterioles and formation of plexiform lesions composed of hyperproliferative endothelial and vascular smooth-muscle cells.
PAH is a disease of the pulmonary vasculature that targets primarily the small pulmonary arteries. The hallmark of terminal PAH is plexiform lesions composed of hyperproliferative PAECs and pulmonary artery smooth-muscle cells (PASMCs) 1 . The abnormal proliferation of these cells probably involves perturbation of the intrinsic characteristics of both of these cell types, but emerging evidence suggests that pathological crosstalk of dysregulated molecular signaling between these cells may also contribute to the disruption of vascular homeostasis [2] [3] [4] [5] [6] [7] .
Recent studies have described an emerging role for the APLN-APLNR (also known as apelin receptor, APJ or AGTRL1) signaling axis in the maintenance of pulmonary vascular homeostasis 8, 9 . APLN is highly expressed in the endothelial cells of both the systemic and pulmonary vasculature 10 . APLNR, thus far the only known receptor for APLN, is also highly expressed in the lungs 11, 12 , where it mediates the autocrine and paracrine effects of APLN in the pulmonary endothelium. Apln knockout mice develop exacerbated pulmonary hypertension in response to hypoxia 8 . APLN levels in the serum and pulmonary endothelium of subjects with PAH are significantly reduced 8, 9, 13 . Studies showing a hyperproliferative, antiapoptotic phenotype of PAH PAECs 14, 15 , in conjunction with other studies showing decreased APLN expression in PAH 8, 9, 13 , suggest the possibility that disruption of APLN signaling in PAH PAECs results in the activation of a secondary signaling cascade that contributes to the aberrant proliferation of these cells.
Serum and urinary FGF2 levels are significantly increased in subjects with PAH and may be important for disease pathogenesis 16 . A more recent study showed that the PAECs may be the primary source of the elevated FGF2 levels in subjects with PAH 5 . Here we demonstrate the crucial role of an miRNA-based endothelial mechanism that underlies the reciprocal dysregulation of APLN and FGF2 signaling in PAH.
RESULTS

Impaired APLN signaling leads to increased FGF2 expression
Previous studies have demonstrated that APLN expression is significantly reduced in the serum and pulmonary microvascular endothelium of subjects with PAH, as well as in the lungs of rats with monocrotaline (MCT)-induced pulmonary hypertension 8, 9, 13, 17 . In line with these data, we found that APLN expression was significantly decreased in multiple PAEC lines derived from the lungs of subjects with idiopathic or familial PAH (IPAH or FPAH, respectively, referred to generally as PAH herein) compared to control PAECs from unused, explanted normal donor lungs ( Fig. 1a-c) . We found no significant difference in the mRNA levels of APLNR, which was predominantly expressed by the microvascular endothelial layers of the pulmonary vessels, between the two groups ( Supplementary Fig. 1a,b) . We found increased proliferating cellular nuclear antigen (PCNA) staining in the endothelium of PAH microvasculature, as well as increased proliferative responses of PAH PAECs ( Fig. 1c and Supplementary  Fig. 2 ). Whereas augmentation of APLN signaling in normal PAECs led to an increase in PAEC proliferation as previously described 9 , augmentation of APLN signaling in PAH PAECs had the reverse effect and inhibited proliferation (Supplementary Fig. 3) .
Given these findings, we hypothesized that downregulation of APLN in PAH PAECs might contribute to the aberrant activation of a secondary signaling cascade, leading to increased proliferation of PAECs. We evaluated the expression of an array of angiogenic growth factors in normal PAECs subjected to APLN knockdown (Supplementary Fig. 4 ) and found that FGF2 expression was significantly increased ( Fig. 1d) . We also found an inverse correlation between APLN and FGF2 mRNA levels in PAECs from controls and subjects with PAH ( Fig. 1e) . We confirmed this relationship by showing a robust increase in FGF2 expression with APLN knockdown and reciprocally decreased FGF2 expression with APLN overexpression ( Fig. 1f) . Moreover, we found significantly increased FGF2 expression in both total lung homogenates and isolated mouse lung endothelial cells (LECs) of Apln-null mice 18 compared to wild-type mice ( Fig. 1g ).
FGF2 is regulated by miRNAs downstream of APLN signaling
We hypothesized that the regulation of FGF2 by APLN might be mediated by miRNAs that affect the stability of FGF2 mRNA. To test this hypothesis, we first determined whether knockdown of AGO2 (encoding argonaute 2), a key catalytic core component of the RNAinduced silencing complex, affected FGF2 expression in PAECs. AGO2 knockdown ( Supplementary Fig. 4 ) led to a robust increase in FGF2 protein expression in normal PAECs, suggesting the presence of basal miRNA-directed regulation of FGF2 in PAECs (Fig. 1h) . AGO2 knockdown did not further increase FGF2 expression in PAH PAECs, suggesting that miRNA-mediated control of FGF2 expression may be compromised in these PAECs (Fig. 1h ). In addition, the reduced FGF2 expression seen with APLN overexpression was abrogated by concurrent AGO2 knockdown ( Fig. 1i) .
On the basis of these findings, we attempted to identify miRNAs regulated by APLN that might be involved in FGF2 regulation. We conducted miRNA microarray analyses using normal PAECs subjected to knockdown of APLN, APLNR or both ( Fig. 2a and Supplementary Fig. 5 ). From a total of 14 miRNAs that were significantly downregulated in each of the three conditions ( Supplementary Table 1 ), in silico analysis (http://www. microrna.org/microrna/home.do) identified two that were predicted to target the FGF2 3′ untranslated region (UTR): miR-424 and miR-503. These two miRNAs are separated by 250 bp on the X chromosome and share substantial sequence identity in their seed sequences ( Fig. 2b) . Other miRNAs predicted to target FGF2 in the in silico analysis, including miR-15a, miR-16, miR-195 and miR-497, were not significantly downregulated in the microarray experiments (data not shown). Using real-time quantitative PCR, we confirmed that both the pri and mature forms of miR-424 and miR-503 were significantly downregulated by APLN knockdown (Fig. 2c) , suggesting that the transcription of these miRNAs, rather than their post-transcriptional maturation, is regulated by APLN signaling. We also found that these two miRNAs are transcribed as a single transcript, which was also downregulated by APLN knockdown (Supplementary Fig. 6a,b) . We used the putative promoter of npg the miR-424-miR-503 transcription unit to generate a luciferase reporter construct. The activity of this reporter was robustly induced by APLN overexpression in PAECs ( Fig. 2d) . Moreover, we found decreased levels of mmu-miR-322 (the mouse homolog of hsa-miR-424) and miR-503 in both total lung homogenates and LECs from Apln-null mice ( Fig. 2e) . Expression profiling of various organ tissues from control mice showed high expression of miR-424 and miR-503 in the lungs, where the highest expression of APLN and APLNR had been previously reported ( Fig. 2f) 12, 19 . In situ hybridization of normal human lungs demonstrated robust expression of miR-424 and miR-503 in the luminal layer of the pulmonary microvasculature ( Fig. 2g and Supplementary Fig. 7) .
To validate the predicted targeting of FGF2 by miR-424 and miR-503, we determined the effects of miR-424 and miR-503 overexpression or knockdown on FGF2 expression in PAECs. miR-424 and miR-503 were predicted to target the FGF2 3′ UTR at three separate sites ( Supplementary Fig. 8 ). miR-424 or miR-503 overexpression in normal or PAH PAECs led to significantly decreased FGF2 expression, whereas inhibition of endogenous miR-424 or miR-503 by transfection of anti-miRs in normal PAECs led to increased FGF2 expression ( Fig. 3a and Supplementary Fig. 9a,b ). Furthermore, we generated luciferase constructs with the 3′ UTR sequence of FGF2 and found that miR-424 and miR-503 overexpression led to a robust decrease of luciferase activity (Fig. 3b) . This response was abrogated by mutation of the miR-424-and miR-503-targeted seed sequences ( Fig. 3b) .
miR-424 and miR-503 target FGFR1 and inhibit FGF signaling
We further analyzed the in silico data to identify additional potential targets of miR-424 and miR-503 that might have a role in FGF signaling. FGFR1, encoding FGF receptor 1, was predicted to be targeted by miR-424 (as recently described in ref. 20) and by miR-503, as it has two distinct miR-424-and miR-503-binding sites in its 3′ UTR (Supplementary Fig. 8 ). Overexpression and knockdown of miR-424 and miR-503 in normal and PAH PAECs had effects on FGFR1 that were similar to those on FGF2 expression ( Fig. 3a and Supplementary Fig. 9a,b) . A luciferase reporter bearing the 3′ UTR of FGFR1 was also similarly affected by miR-424 and miR-503 overexpression ( Fig. 3b) . Mutation of the miR-424-and miR-503-targeted seed sequences in the FGFR1 3′ UTR led to complete abrogation of miR-424-and miR-503-mediated inhibition of luciferase reporter activity ( Fig. 3b) . Moreover, APLN knockdown resulted in robust increases of FGF2 and FGFR1 expression that were abrogated with concurrent overexpression of miR-424 and miR-503 ( Fig. 3c) .
We next determined whether perturbation of miR-424 and miR-503 expression affected the phosphorylation of ERK1 and ERK2 (ERK1/2), key downstream targets of FGF2-FGFR1 signaling in endothelial cells 21 . ERK1/2 phosphorylation was decreased by miR-424 and miR-503 overexpression both in the basal state and with exogenous FGF2 stimulation ( Fig. 3d) ; this effect may be secondary to a reduction of FGFR1 expression. In addition, transfection of anti-miRs targeting miR-424 and miR-503 led to a significant increase in ERK1/2 phosphorylation ( Fig. 3e) .
Altered miRNA-FGF axis in PAH PAECs
The finding that APLN expression is decreased in PAH PAECs led us to test whether miR-424 and miR-503 expression would also be reduced in these cells. Indeed, we found significantly decreased expression of the mature, pri and pre forms of miR-424 and miR-503 in PAECs derived from subjects with PAH as compared to PAECs from control subjects ( Fig. 4a and Supplementary Fig. 10a,b) . Moreover, FGF2 mRNA levels were also increased in PAH PAECs (Fig. 4a) .
There was a significant linear correlation between the mRNA levels of APLN and miR-424 as well as between expression of miR-424 and miR-503 ( Fig. 4b) . We also found a significant inverse correlation npg between the levels of miR-424 and those of FGF2 and FGFR1, and between the levels of miR-503 and those of FGF2 and FGFR1 ( Fig. 4b and Supplementary Fig. 11 ). As assessed by western blotting, FGF2 and FGFR1 protein expression were markedly higher in PAH PAECs (Fig. 4c) . In addition, immunohistochemistry in lung samples of unused explanted normal donors and subjects with PAH showed substantially higher expression of FGFR1 in the endothelial layer of the PAH lung, as demonstrated by colocalization with von Willebrand factor (vWF) ( Fig. 4d) . In situ hybridization of lungs from subjects with PAH showed markedly lower levels of miR-424 and miR-503 in the microvasculature compared to control donor lungs ( Fig. 4e and Supplementary Fig. 12 ).
miR-424 and miR-503 promote PAEC quiescence
We studied human PAECs in cell culture to further evaluate the functional roles of miR-424 and miR-503. We found that the endogenous expression levels of miR-424 and miR-503 increased as the PAECs reached a confluent state or in serum-starvation conditions npg (Supplementary Fig. 13 ). Cell-cycle analysis showed that miR-424 and miR-503 overexpression using miRNA mimics induced cellcycle arrest at the G0/G1 stage in both normal and PAH PAECs (Fig. 5a) . Overexpression of miR-424 and miR-503 also led to significantly decreased proliferation of both normal and PAH PAECs, whereas FGFR1 transfection (lacking its 3′ UTR) in conjunction with FGF2 stimulation reversed the inhibition of proliferation resulting from miR-424 and miR-503 overexpression in both normal and PAH PAECs ( Fig. 5b and Supplementary Fig. 14) . Moreover, the increased proliferation of normal PAECs in response to APLN overexpression was further augmented with concurrent inhibition of miR-424 and miR-503, and inhibition of miR-424 and miR-503 reversed the antiproliferative effect of APLN overexpression in PAH PAECs (Supplementary Fig. 3b ). Fig. 4 ) led to significantly (P < 0.05) reduced proliferation of PAH PAECs (Supplementary Fig. 14) . Inhibition of miR-424 and miR-503 led to significantly increased proliferation of normal PAECs but had minimal effect on PAH PAECs (Fig. 5c ). In addition, concurrent knockdown of FGF2 and FGFR1 completely antagonized the proliferative effects of miR-424 and miR-503 inhibition in control PAECs and inhibited proliferation of PAH PAECs, which were unaffected by miR-424 and miR-503 inhibition (Fig. 5c) . Overexpression of miR-424 and miR-503 in control and PAH PAECs also reduced cell migration ( Fig. 5d,e) ; this effect in control PAECs was reversed by restoration of FGF2 and FGFR1 expression ( Fig. 5d) .
Transfection of siRNAs targeting FGF2 and FGFR1 (Supplementary
Endothelial miR-424 and miR-503 inhibit PASMC proliferation
As PAH is a vascular disease that is characterized by hyperproliferation of both PAECs and PASMCs, we measured miR-424 and miR-503 expression in control and PAH PASMCs. PASMCs had significantly (P < 0.001) lower transcript levels of miR-424 and miR-503 than PAECs (Supplementary Fig. 15a) . Moreover, miR-424 or miR-503 expression in PAH PASMCs was not significantly different as compared to control PASMCs (Supplementary Fig. 15b) .
We next evaluated whether overexpression of miR-424 and miR-503 in PAECs affected the proliferation of PASMCs in a paracrine manner. Incubation of normal PASMCs with conditioned medium from normal PAECs resulted in a significant increase in PASMC proliferation, and this effect was even greater using conditioned medium from PAH PAECs (Fig. 5f) . Conditioned medium from either normal or PAH PAECs transfected with miR-424 and miR-503 had a significantly (P < 0.01) reduced effect on PASMC proliferation as compared to conditioned medium from control normal or PAH PAECs, respectively. Moreover, this effect of miR-424 and miR-503 transfection was abrogated by concurrent transfection with an FGF2 overexpression construct, demonstrating the ability of FGF2 to reverse the paracrine effects of miR-424 and miR-503 ( Fig. 5f) . Moreover, conditioned medium from normal PAECs subjected to APLN knockdown induced a significantly higher level of PASMC proliferation as compared to conditioned medium from control cells; this effect of APLN knockdown was abrogated by concurrent overexpression of miR-424 and miR-503 ( Fig. 5g) . Conditioned medium from normal PAECs subjected to FGF2 knockdown was less effective in inducing PASMC proliferation than conditioned medium from control cells, and concurrent knockdown of FGF2 abrogated the effect of APLN knockdown in this assay (Fig. 5h) .
miR-424 and miR-503 ameliorate pulmonary hypertension
We evaluated the expression levels of rno-miR-322 (the rat homolog of hsa-miR-424), miR-503, FGF2 and FGFR1 in two experimental rat models of pulmonary hypertension: the MCT model and the SU-5416/hypoxia (SuHx) model 22, 23 . Compared to control rats, rats subjected to MCT or SuHx had significantly decreased expression of miR-322 and miR-503 in their lungs and in isolated LECs and decreased Apln expression in LECs, as well as robust increases in FGF2 and FGFR1 expression in the lungs (Fig. 6a,b) . We validated the signaling axis comprising miR-322 (miR-424), miR-503, FGF2 and FGFR1 in rats by demonstrating that expression of FGF2 and FGFR1 in isolated rat LECs were significantly (P < 0.01) downregulated by overexpression of rno-miR-322 or rno-miR-503 mimics ( Supplementary  Fig. 16 ) or human miR-424 or miR-503 (data not shown). We evaluated the efficacy of miR-424 and miR-503 restoration in ameliorating the severity of pulmonary hypertension in three experimental models: (i) the MCT prevention model, (ii) the MCT rescue model and (iii) the SuHx rescue model (Supplementary Fig. 17 ). We used intranasal delivery of either GFP-expressing control lentivirus (GFP) or lentivirus expressing miR-424, miR-503 and GFP (424/503-GFP, 2 × 10 10 PFU per intranasal delivery) to induce expression of these miRNAs in the lungs (n = 6-9 mice in each group). We confirmed expression of the lentiviral-encoded miRNAs by detection of lentiviralspecific miR-424 and miR-503 transcripts in lung homogenates and isolated LECs of 424/503-GFP-treated rats, which were absent in the GFP treatment group (Supplementary Fig. 18a ). We also confirmed the efficacy of our delivery method by detection of lentivirally expressed GFP in lungs from both 424/503-GFP-treated and GFPtreated rats but not in lungs from control rats not subjected to intranasal lentivirus delivery (Supplementary Fig. 18b ). We confirmed endothelial infection by flow cytometry that identified a CD31 + GFP + cell population (~8% of total CD31 + cells) in the lentiviral groups (Supplementary Fig. 18c ). In addition, 424/503-GFP treatment in the SuHx model restored miR-424 (rno-miR-322 and lentivirally expressed hsa-miR-424) and miR-503 levels in isolated LECs to levels comparable to those in the nondiseased control state (Supplementary Fig. 18d ).
In all three models, right ventricular systolic pressure (RVSP) was significantly increased (Fig. 6c) . RVSP was markedly reduced in rats that received intranasal 424/503-GFP compared to those that received GFP in all three models (Fig. 6c) . We also found a significant reduction (P < 0.05) in the right ventricle to the left ventricle plus septum weight ratio in the 424/503-GFP treatment groups in the three models (Supplementary Fig. 19 ). The number of muscularized microvessels was also significantly lower in the 424/503-GFP treatment groups in each of the three models (Fig. 6d) . To evaluate vascular cell proliferation, we performed PCNA staining in conjunction with vWF staining. The number of PCNA-positive microvessels was increased in pulmonary hypertension rats in the GFP treatment groups as compared to nondiseased controls, whereas the 424/503-GFP treatment groups had significantly fewer PCNA-positive microvessels compared to the GFP treatment groups (Fig. 6e) . Similarly, the number of obliterated vessels was increased in the GFP treatment group in the SuHx model as compared to nondiseased controls, an effect that was ameliorated by 424/503-GFP treatment (Fig. 6f) . The expression of FGF2 and FGFR1 was significantly decreased in total lung homogenates of the 424/503-GFP treatment groups compared to the respective GFP treatment groups (Fig. 6g) . Moreover, isolated LECs in the GFP treatment groups of the MCT and SuHx models also had significantly elevated FGF2 and FGFR1 expression, which was significantly reduced in the respective 424/503-GFP treatment groups (Fig. 6g) , further validating the miR-424, miR-503, FGF2 and FGFR1 signaling axis.
DISCUSSION
Recent studies have associated decreased APLN expression with clinical PAH 8, 9, 13 . In addition, abnormally elevated FGF2 expression has also been linked with PAH 5, 16 . Here we describe miRNA-driven regulation of FGF signaling by APLN, integrating these isolated clinical observations into a cohesive mechanism.
The importance of APLN signaling in pulmonary vascular homeostasis has been demonstrated by studies showing exacerbation of hypoxia-induced pulmonary hypertension in Apln-null mice and the reversal of disease by exogenous APLN peptide administration in both the MCT model and endothelial-specific peroxisome proliferator activated receptor γ (PPAR-γ) knockout mice 8, 9, 17 . Our findings provide four major conclusions: (i) disruption of APLN signaling in PAECs results in increased expression of FGF2 and FGFR1; (ii) APLN regulates miR-424 and miR-503 expression, which in turn target two key components of endothelial FGF signaling, FGF2 and FGFR1; (iii) downregulation of APLN, miR-424 and miR-503 in PAH PAECs is associated with increased FGF2 and FGFR1 expression and hyperproliferation of PAECs and PASMCs, and (iv) restoration of miR-424 and miR-503 in the lungs inhibits FGF2 and FGFR1 expression and ameliorates pathology in experimental models of pulmonary hypertension.
The downstream targets of APLN in the context of the pulmonary vasculature remain to be fully elucidated. Our current findings demonstrate that APLN signaling, in a miR-424-and miR-503dependent manner, has a crucial role in regulating the magnitude of FGF signaling in the pulmonary vasculature (Fig. 6h) . Although basal FGF signaling activity has been found to be essential for endothelial homeostasis 21 , pathological augmentation of FGF signaling is associated with the cellular hyperproliferation and vascular remodeling found in PAH 5, 16, 24 . These findings indicate that the maintenance of delicately balanced FGF signaling is essential for the preservation of pulmonary vascular homeostasis.
Previous studies have suggested proliferative effects of APLN on endothelial cells 25, 26 . However, these effects have been modest at best, and another study was unable to confirm such findings 27 , suggesting strong context dependence for the effects of APLN on the endothelium. APLN seems to have the greatest proliferative and migratory effects in the developing vasculature [28] [29] [30] , but these findings have not been convincingly extended to the mature endothelium. Rather, emerging evidence suggests that the role of APLN signaling in mature vessels is to preserve a differentiated and quiescent endothelial layer. This role is mediated at least in part by induction of KLF2 expression and nitric oxide synthase 3 (NOS3 or eNOS) expression and activity 8 . APLN also enhances endothelial layer integrity by maintenance of membranous CDH5 (VE-cadherin) expression 31 . Our current data point to a third role in which APLN induces miR-424 and miR-503 expression to repress aberrant, pathologic cellular growth and proliferation. It is worth noting that in addition to the cellular growthinhibitory effects described here of the APLN, miR-424 and miR-503 axis, APLN signaling can also promote cellular growth through other signaling targets, as has been previously described 9 . Nevertheless, our demonstration of a marked reduction in APLN, miR-424 and miR-503 expression and the consequent signaling perturbations in npg PAH PAECs demonstrates the importance of this signaling axis in the pulmonary vasculature.
Prior work demonstrated that increased production of FGF2 from the PAECs may have an important role in the pathogenesis of PAH 5, 16, 24 . However, the mechanism of this dysregulation has remained undefined. Our study identifies a cell-intrinsic, miRNAmediated regulation of FGF signaling that is disrupted in the pulmonary endothelium of subjects with PAH. Our data also provide a mechanism by which restoration of miR-424 and miR-503 expression in PAECs can regulate PASMC growth in a paracrine manner. These findings lend further support to the emerging role of PAEC-PASMC crosstalk that likely has an important role in the pathogenesis of PAH [5] [6] [7] .
Although no prior studies to our knowledge have demonstrated a role for miR-424 or miR-503 in PAH, miR-322 (miR-424) was found to be significantly downregulated in array analyses evaluating the MCT model of pulmonary hypertension in rats 32 . Studies have also implicated miR-424 and miR-503 in promoting the differentiation of monocytes, macrophages and skeletal muscle 33, 34 . A recent study demonstrated targeting of vascular endothelial growth factor (VEGF), VEGFR2 and FGFR1 by miR-424 in human umbilical vein endothelial cells, but a separate study indicated that miR-424 may have a proangiogenic function in hypoxic endothelial cells, suggesting a context-dependent role for miR-424 (refs. 20,35) . Further investigations to define the mechanism of APLN-mediated regulation of miR-424 and miR-503 are ongoing and will provide greater insights into the mechanism regulating the endothelial expression and function of these miRNAs.
Although we cannot completely rule out the possibility that other validated targets of miR-424 and miR-503, such as cyclin E1 (CCNE1), cdc25A, mitogen-activated protein kinase kinase 1 (MEK1), VEGF and VEGFR2 may also contribute to the PAEC phenotype of subjects with PAH, we found no significant changes in their expression levels in PAH PAECs (J.K. and H.J.C., unpublished data). Furthermore, we found that restoration or abrogation of FGF signaling was sufficient to fully counter the effects of either overexpression or knockdown of miR-424 and miR-503 in PAECs, respectively. It is possible that additional predicted but not yet validated targets of miR-424 and miR-503 may also contribute to the cellular and in vivo consequences of modulating these miRNAs. Given that the current study focused on the regulatory mechanism that links APLN signaling to the FGF2 signaling cascade in the pulmonary vasculature, future studies will be needed to evaluate the role of other validated and predicted targets of miR-424 and miR-503 in the context of PAH.
Our findings delineate a relationship between the APLN and FGF signaling pathways in the pulmonary vasculature that is mediated by two APLN-responsive miRNAs: miR-424 and miR-503. Downregulation of these miRNAs is associated with both human PAH and established experimental rodent models. These findings support development of new therapeutic strategies designed to augment APLN, miR-424 and miR-503 signaling, as well as to inhibit FGF signaling.
METHODS
Methods and any associated references are available in the online version of the paper.
